"Paclitaxel" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A cyclodecane isolated from the bark of the Pacific yew tree, TAXUS BREVIFOLIA. It stabilizes MICROTUBULES in their polymerized form leading to cell death.
| Descriptor ID |
D017239
|
| MeSH Number(s) |
D02.455.426.392.368.242.888.777 D02.455.849.291.850.777
|
| Concept/Terms |
Taxol- Taxol
- Taxol A
- Bris Taxol
- Taxol, Bris
|
Below are MeSH descriptors whose meaning is more general than "Paclitaxel".
Below are MeSH descriptors whose meaning is more specific than "Paclitaxel".
This graph shows the total number of publications written about "Paclitaxel" by people in this website by year, and whether "Paclitaxel" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2003 | 1 | 0 | 1 |
| 2005 | 1 | 0 | 1 |
| 2006 | 0 | 1 | 1 |
| 2007 | 0 | 1 | 1 |
| 2008 | 1 | 1 | 2 |
| 2009 | 2 | 0 | 2 |
| 2010 | 1 | 1 | 2 |
| 2011 | 1 | 3 | 4 |
| 2013 | 0 | 1 | 1 |
| 2015 | 1 | 1 | 2 |
| 2016 | 0 | 2 | 2 |
| 2017 | 14 | 19 | 33 |
| 2018 | 17 | 22 | 39 |
| 2019 | 4 | 10 | 14 |
To return to the timeline, click here.
Below are the most recent publications written about "Paclitaxel" by people in Profiles.
-
The Mechanisms of the Growth Inhibitory Effects of Paclitaxel on Gefitinib-resistant Non-small Cell Lung Cancer Cells. Cancer Genomics Proteomics. 2021 Sep-Oct; 18(5):661-673.
-
Use of Immunotherapy in Patients With Cancer During the COVID-19 Pandemic. Oncology (Williston Park). 2020 09 15; 34(9):370-376.
-
The Need of Research Initiatives Amidst and After the Covid-19 Pandemic: A Message from the Editors of the EJVES. Eur J Vasc Endovasc Surg. 2020 05; 59(5):695-696.
-
Mortality Assessment of Paclitaxel-Coated Balloons: Patient-Level Meta-Analysis of the ILLUMENATE Clinical Program at 3 Years. Circulation. 2019 10; 140(14):1145-1155.
-
Taking paclitaxel coated balloons to a higher level: Predicting coating dissolution kinetics, tissue retention and dosing dynamics. J Control Release. 2019 09 28; 310:94-102.
-
A phase II study of nab-paclitaxel and carboplatin chemotherapy plus necitumumab in the first-line treatment of patients with stage IV squamous non-small cell lung cancer. Lung Cancer. 2019 10; 136:52-56.
-
Effective Delivery of a Microtubule Polymerization Inhibitor Synergizes with Standard Regimens in Models of Pancreatic Ductal Adenocarcinoma. Clin Cancer Res. 2019 09 15; 25(18):5548-5560.
-
Spatial distribution of IL4 controls iNKT cell-DC crosstalk in tumors. Cell Mol Immunol. 2020 05; 17(5):496-506.
-
Co-Delivery of Paclitaxel and PLK1-Targeted siRNA Using Aptamer-Functionalized Cationic Liposome for Synergistic Anti-Breast Cancer Effects In Vivo. J Biomed Nanotechnol. 2019 Jun 01; 15(6):1135-1148.
-
Trebananib or placebo plus carboplatin and paclitaxel as first-line treatment for advanced ovarian cancer (TRINOVA-3/ENGOT-ov2/GOG-3001): a randomised, double-blind, phase 3 trial. Lancet Oncol. 2019 06; 20(6):862-876.